Drug Approval | June 24, 2022
Rivaroxaban approved in Japan for patients with PAD after revascularisation
It´s the first trial to demonstrate the benefits of dual pathway inhibition
It´s the first trial to demonstrate the benefits of dual pathway inhibition
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
The company is now introducing the product into the India pharmaceutical market.
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
Subscribe To Our Newsletter & Stay Updated
